A randomized trial found Cepheid’s Xpert Xpress MVP test improved appropriate treatment rates for vaginitis within 24 hours compared to standard diagnostic methods.
Cepheid announced the publication of a study in the journal Sexually Transmitted Diseases demonstrating the real-world impact of the Xpert Xpress MVP (multiplex vaginal panel) test when used at the point of care. The study found that women with vaginitis symptoms were significantly more likely to receive appropriate treatment within 24 hours of their clinic visit when tested with the multiplex panel compared to standard diagnostic methods.
The randomized clinical trial, led by investigators at Magee-Womens Research Institute and the University of Pittsburgh, evaluated the utility of a multiplex molecular test for vaginitis at the point of care. Standard methods, which include symptom-based assessment and microscopy, remain common in clinical practice despite limitations in accuracy.
Limitations of Traditional Diagnostics
The study provided insight into current diagnostic practices for vaginitis, which often involve overlapping symptoms like abnormal discharge, itching, or irritation. Investigators reported that 25% of healthcare providers relied solely on symptoms to guide treatment decisions, and standard approaches correctly identified infections only about 50% to 63% of the time.
These findings reinforce challenges associated with microscopy-based diagnosis, such as variable accuracy and inconsistent use. Because vaginal symptoms are often nonspecific and can occur in women without an infection, the study highlights the limitations of management based on symptoms alone.
Significant Improvement in Appropriate Treatment
Women tested with the Xpert Xpress MVP were significantly more likely to receive appropriate treatment within 24 hours than those receiving usual care. The findings also highlighted a reduced risk of overtreatment. Among women with no detectable vaginal pathogens, 50.0% received unnecessary treatment with usual care, compared to 27.1% of those tested with the multiplex molecular test.
“Overuse of antimicrobials when no pathogens are detected should be avoided since it can contribute to antimicrobial resistance, may disrupt the vaginal microbiome, may cause side effects, and adds costs to women and their insurers,” the study authors say in a release.
Healthcare providers involved in the study reported positive perceptions of the technology, with 87% indicating they would like to incorporate this type of testing into routine clinical practice.
“Women presenting with vaginal symptoms deserve accurate answers and timely, evidence-based care,” says Connie Savor, chief medical officer at Cepheid, in a release. “This study demonstrates how molecular point-of-care tests, such as Xpert Xpress MVP, can help clinicians make more informed treatment decisions in a single visit, improving care while reducing unnecessary treatment.”
Test Specifications
The Xpert Xpress MVP is a Food and Drug Administration-cleared, Clinical Laboratory Improvement Amendments-waived polymerase chain reaction test. Using a single vaginal swab specimen that can be clinician- or self-collected in a clinical setting, the test detects the causative agents of bacterial vaginosis and vulvovaginal candidiasis, and trichomoniasis, including co-infections.
The test runs on the GeneXpert and GeneXpert Xpress systems and provides results in approximately one hour. The study was supported by an investigator-initiated grant from Cepheid.
Photo caption: Depiction of Xpert Xpress MVP in-office testing
Photo credit: Cepheid
